middle and advanced squamous cells esophageal cancer
Conditions
Interventions
Experimental group:Apatinib and sequential chemoradiotherapy
control group:sequential chemoradiotherapy
Sponsors
Nanchong Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18-70 years; 2. Making a definite diagnosis of squamous cells esophageal cancer in pathology; 3. The stages between II/III stage; 4. At the beginning of treatment; 5. The size of tumour to be able to measured; 7. ECOG=2 scores. 8. Except survival time at least 6 months; 9. WBC=4×10^9/L, ANC=2×10^9/L, HGB =90 g/L, PLT=90×10^9/L; 10. Liver and kidney function ALT, AST, STBS, CR50%, DLCO measured value/predicted value>80%.
Exclusion criteria
Exclusion criteria: 1. Having remote cancer transfer; 2. Having already received surgeryradiotherapychemotherapyor target treat; 3. Be diagnosed in other cancer in 5 years (except cervical carcinoma in situbasal cell carcinoma in skinUrothelial carcinomaearly stage prostatic carcinoma); 4. Be received other medicinal trials in 1 mouth; 5. Pregnant or?breast-feedor refuse to receive birth control duration of Therapy women; 6. Having serious?allergy history; 7. Having Serious Lung or heart disease; 8. Refusing or can not sign informed consent; 9. Misusing of drugs or alcohol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR;PFS; | — |
Countries
China
Contacts
Public ContactHu Xingsheng
Nanchong Central Hospital
Outcome results
None listed